The company already told the market the primary objective failed, they just said that it was "expected" and the market bought it. Why anyone would believe that a company would design a clinical trial with a primary objective that was expected to fail is not something I can answer. You can not get a trial approved with a primary objective that is expected to fail - it would be considered unethical.
Get answers to the three questions I posted and you will all have a lot better idea of the probability that BIT225 will be picked up by a large pharma company.
The company already told the market the primary objective...
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
0.001(2.63%) |
Mkt cap ! $17.59M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 2.0¢ | 1.9¢ | $11.54K | 604.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 1466986 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 830622 | 7 |
View Market Depth
| Last trade - 15.55pm 15/11/2024 (20 minute delay) ? |
| BIT (ASX) Chart |